Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103 USD | +1.39% |
|
+0.70% | -6.38% |
Jul. 10 | Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121 | MT |
Jul. 10 | DexCom, Inc. : A Must-Have Tool for Diabetes Care | ![]() |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.38% | 179B | |
-6.46% | 98.81B | |
-8.19% | 64.7B | |
-10.72% | 44.06B | |
+8.30% | 43.8B | |
+17.84% | 44.56B | |
+9.16% | 28.28B | |
+20.27% | 25.89B | |
-8.74% | 23.41B | |
-12.16% | 21.99B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121